BioSyent Inc. (CVE:RX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$15.96 and last traded at C$15.81, with a volume of 4331 shares. The stock had previously closed at C$15.70.
BioSyent Price Performance
The firm has a market cap of C$178.86 million, a PE ratio of 18.51 and a beta of 1.00. The stock has a 50 day simple moving average of C$14.66 and a two-hundred day simple moving average of C$14.68. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07.
Insider Buying and Selling at BioSyent
In other BioSyent news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total value of C$27,600.60. Following the sale, the director directly owned 37,261 shares of the company’s stock, valued at approximately C$545,873.65. This trade represents a 4.81% decrease in their ownership of the stock. Insiders have sold a total of 4,058 shares of company stock valued at $58,902 in the last three months. Corporate insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Read More
- Five stocks we like better than BioSyent
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
- Photronics Is Quietly Becoming a Key Winner From the AI Boom
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
